Fluvastatin Causes NLRP3 Inflammasome-Mediated Adipose Insulin Resistance
- 13 October 2014
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 63 (11), 3742-3747
- https://doi.org/10.2337/db13-1398
Abstract
Statins reduce lipid levels and are widely prescribed. Statins have been associated with an increased incidence of type 2 diabetes, but the mechanisms are unclear. Activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3)/caspase-1 inflammasome, promotes insulin resistance, a precursor of type 2 diabetes. We showed that four different statins increased interleukin-1β (IL-1β) secretion from macrophages, which is characteristic of NLRP3 inflammasome activation. This effect was dose dependent, absent in NLRP3(-/-) mice, and prevented by caspase-1 inhibition or the diabetes drug glyburide. Long-term fluvastatin treatment of obese mice impaired insulin-stimulated glucose uptake in adipose tissue. Fluvastatin-induced activation of the NLRP3/caspase-1 pathway was required for the development of insulin resistance in adipose tissue explants, an effect also prevented by glyburide. Fluvastatin impaired insulin signaling in lipopolysaccharide-primed 3T3-L1 adipocytes, an effect associated with increased caspase-1 activity, but not IL-1β secretion. Our results define an NLRP3/caspase-1-mediated mechanism of statin-induced insulin resistance in adipose tissue and adipocytes, which may be a contributing factor to statin-induced development of type 2 diabetes. These results warrant scrutiny of insulin sensitivity during statin use and suggest that combination therapies with glyburide, or other inhibitors of the NLRP3 inflammasome, may be effective in preventing the adverse effects of statins.Keywords
This publication has 27 references indexed in Scilit:
- HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activationJournal of Leukocyte Biology, 2013
- Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 DiabetesDiabetes, 2012
- Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialThe Lancet, 2012
- Statins and Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health InitiativeJAMA Internal Medicine, 2012
- Inflammatory Mechanisms in ObesityAnnual Review of Immunology, 2011
- Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signalingNature Immunology, 2011
- A role for geranylgeranylation in interleukin‐1β secretionArthritis & Rheumatism, 2006
- Statin therapy and autoimmune disease: from protein prenylation to immunomodulationNature Reviews Immunology, 2006
- Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 1999